Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and small molecule therapies for ophthalmic disorders, has announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference.
CEO George Magrath, M.D. will participate in a fireside chat that will be available on demand starting Wednesday, August 13, 2025 at 7:00 a.m. ET. Investors can access the webcast through the Events section of Opus Genetics' website.
Opus Genetics (Nasdaq: IRD), un'azienda biofarmaceutica in fase clinica specializzata in terapie geniche per malattie ereditarie della retina e terapie con piccole molecole per disturbi oftalmici, ha annunciato la sua partecipazione al 5掳 Congresso Annuale Virtuale di Oftalmologia H.C. Wainwright.
Il CEO George Magrath, M.D. prender脿 parte a una conversazione informale disponibile on demand a partire da mercoled矛 13 agosto 2025 alle 7:00 a.m. ET. Gli investitori potranno accedere alla trasmissione web tramite la sezione Eventi del sito web di Opus Genetics.
Opus Genetics (Nasdaq: IRD), una empresa biofarmac茅utica en fase cl铆nica centrada en terapias g茅nicas para enfermedades hereditarias de la retina y terapias con peque帽as mol茅culas para trastornos oft谩lmicos, ha anunciado su participaci贸n en la 5陋 Conferencia Anual Virtual de Oftalmolog铆a de H.C. Wainwright.
El CEO George Magrath, M.D. participar谩 en una charla informal que estar谩 disponible bajo demanda a partir del mi茅rcoles 13 de agosto de 2025 a las 7:00 a.m. ET. Los inversores pueden acceder a la transmisi贸n a trav茅s de la secci贸n de Eventos en el sitio web de Opus Genetics.
Opus Genetics (雮橃姢雼�: IRD)电� 鞙犾爠靹� 毵濍 歆堩櫂鞚� 鞙勴暅 鞙犾爠鞛� 旃橂鞝滌檧 鞎堦臣 歆堩櫂鞚� 鞙勴暅 靻岆秳鞛� 旃橂鞝滌棎 歆戩頃樀鐢 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 鞝滌暯 須岇偓搿�, H.C. Wainwright 鞝�5須� 鞐半 鞎堦臣 臧�靸� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
CEO George Magrath, M.D.电� 2025雲� 8鞗� 13鞚� 靾橃殧鞚� 鞓れ爠 7鞁�(霃欕秬鞁滉皠)攵�韯� 欤茧順曥溂搿� 鞝滉车霅樀鐢 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� Opus Genetics 鞗轨偓鞚错姼鞚� 鞚措菠韸� 靹轨厴鞚� 韱淀暣 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃� 靾� 鞛堨姷雼堧嫟.
Opus Genetics (Nasdaq : IRD), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les th茅rapies g茅niques pour les maladies h茅r茅ditaires de la r茅tine et les th茅rapies par petites mol茅cules pour les troubles ophtalmiques, a annonc茅 sa participation 脿 la 5e Conf茅rence Annuelle Virtuelle d鈥橭phtalmologie H.C. Wainwright.
Le PDG George Magrath, M.D. participera 脿 une discussion informelle disponible 脿 la demande 脿 partir du mercredi 13 ao没t 2025 脿 7h00 ET. Les investisseurs peuvent acc茅der au webinaire via la section 脡v茅nements du site internet d鈥橭pus Genetics.
Opus Genetics (Nasdaq: IRD), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Gentherapien f眉r erbliche Netzhauterkrankungen und Kleinmolek眉ltherapien f眉r ophthalmologische Erkrankungen spezialisiert hat, hat seine Teilnahme an der 5. j盲hrlichen virtuellen Ophthalmologie-Konferenz von H.C. Wainwright 补苍驳别办眉苍诲颈驳迟.
CEO George Magrath, M.D. wird an einem Fireside-Chat teilnehmen, der ab Mittwoch, den 13. August 2025, um 7:00 Uhr ET auf Abruf verf眉gbar sein wird. Investoren k枚nnen den Webcast 眉ber den Bereich 鈥濫vents鈥� auf der Webseite von Opus Genetics aufrufen.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that George Magrath, M.D., Chief Executive Officer, will participate in a fireside chat during the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference, which will be available on demand on Wednesday, August 13, 2025 at 7:00 a.m. ET.
A link to the live and archived webcast may be accessed on Opus Genetics鈥� website under the Investors section: .
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases. The Company鈥檚 pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown encouraging early results. Additional programs include OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA. Opus Genetics is also advancing Phentolamine Ophthalmic Solution
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
Media
Kimberly Ha
KKH Advisors
917-291-5744
FAQ
When is Opus Genetics (IRD) presenting at the H.C. Wainwright Ophthalmology Conference 2025?
Who will represent Opus Genetics at the H.C. Wainwright Conference 2025?
How can investors access Opus Genetics' (IRD) presentation at the H.C. Wainwright Conference?
What is Opus Genetics' (IRD) main business focus?
